The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Neomile Corporate Advisory Ltd
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neomile Corporate Advisory Ltd (not a promoter of Anlon Healthcare) bought 22,54,422 equity shares (4.24%) via open market between 9th and 11th September 2025. This lifted its stake from 8.67% (46,06,839 shares) to 12.91% (68,61,261 shares), crossing the 10% substantial acquisition threshold that triggers mandatory disclosure under Reg 29(2). The acquisition was carried out in the cash market on both BSE and NSE, with the company's total equity share capital remaining at 5,31,51,500 shares. As Neomile is not part of the promoter group, this is an external investor increasing its strategic holding in the company.
A non-promoter entity crossing the 10% mark signals a significant block investor building a sizable position, which may be viewed positively as institutional validation but could also raise questions about potential further buying or future exit risk. Shareholders should monitor whether Neomile continues to accumulate, as crossing 14% would require another disclosure under the creeping acquisition framework.